BPC-157 Provides Long-Lasting Stomach Protection Against Chronic Alcohol Damage
BPC-157, ranitidine, and propranolol all provided chronic cytoprotection against alcohol-induced gastric lesions in rats, with BPC-157 showing persistent benefit throughout the chronic alcohol exposure period.
Quick Facts
What This Study Found
BPC-157 provided sustained chronic cytoprotection against alcohol-induced gastric lesions, with effectiveness maintained throughout prolonged alcohol exposure alongside liver protection documented in companion study.
Key Numbers
How They Did This
Animal study in rats with chronic alcohol administration (3.03 or 7.28 g/kg/day). BPC-157, ranitidine, and propranolol tested for prevention, attenuation, and reversal of chronic gastric lesions.
Why This Research Matters
Chronic drinkers need sustained stomach protection. BPC-157's persistent effectiveness during prolonged alcohol exposure is practically important for real-world alcohol-related gastropathy.
The Bigger Picture
Combined with its liver protection (companion study), BPC-157 shows the ability to protect both stomach and liver during chronic alcohol exposure — addressing the two organs most damaged by alcoholism.
What This Study Doesn't Tell Us
Rat model. Chronic alcohol doses are standardized; human drinking patterns vary. BPC-157 dosing optimization for chronic use not established.
Questions This Raises
- ?Can BPC-157 protect the entire GI tract during chronic alcohol use?
- ?Does tolerance develop with very long-term BPC-157 use?
- ?Is the gastroprotection mechanism different for chronic versus acute alcohol damage?
Trust & Context
- Key Stat:
- Sustained chronic protection BPC-157 didn't lose effectiveness during prolonged alcohol exposure — maintained gastroprotection throughout the chronic drinking period
- Evidence Grade:
- Preliminary animal evidence with chronic exposure design providing clinically relevant duration data for gastroprotection.
- Study Age:
- Published in 2001. Companion to the portal hypertension study, together demonstrating BPC-157's dual stomach-liver protection.
- Original Title:
- Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.
- Published In:
- Journal of physiology, Paris, 95(1-6), 295-301 (2001)
- Authors:
- Prkacin, I(13), Aralica, G(15), Perovic, D(15), Separovic, J, Gjurasin, M, Lovric-Bencic, M, Stancic-Rokotov, D, Ziger, T, Anic, T, Sikiric, P, Seiwerth, S, Staresinic, M, Mise, S, Rotkvic, I, Jagic, V, Rucman, R, Petek, M, Turkovic, B, Marovic, A, Sjekavica, I, Sebecic, B, Boban-Blagaic, A, Ivasovic, Z
- Database ID:
- RPEP-00691
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does BPC-157 still work after prolonged use?
Yes. Unlike some drugs that lose effectiveness over time, BPC-157 maintained its stomach protection throughout chronic alcohol exposure in rats — no evidence of tolerance.
Can it protect both stomach and liver?
Together with the companion study showing portal hypertension and liver protection, BPC-157 protects the two organs most damaged by chronic alcohol — stomach and liver — simultaneously.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00691APA
Prkacin, I; Aralica, G; Perovic, D; Separovic, J; Gjurasin, M; Lovric-Bencic, M; Stancic-Rokotov, D; Ziger, T; Anic, T; Sikiric, P; Seiwerth, S; Staresinic, M; Mise, S; Rotkvic, I; Jagic, V; Rucman, R; Petek, M; Turkovic, B; Marovic, A; Sjekavica, I; Sebecic, B; Boban-Blagaic, A; Ivasovic, Z. (2001). Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.. Journal of physiology, Paris, 95(1-6), 295-301.
MLA
Prkacin, I, et al. "Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats.." Journal of physiology, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine..." RPEP-00691. Retrieved from https://rethinkpeptides.com/research/prkacin-2001-chronic-cytoprotection-pentadecapeptide-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.